AVEO Pharmaceuticals, Inc. (AVEO): Price and Financial Metrics

AVEO Pharmaceuticals, Inc. (AVEO): $3.97

-0.03 (-0.75%)

POWR Rating

Component Grades













Add AVEO to Watchlist
Sign Up

Industry: Biotech



in industry


  • AVEO scores best on the Growth dimension, with a Growth rank ahead of 91.15% of US stocks.
  • The strongest trend for AVEO is in Value, which has been heading up over the past 179 days.
  • AVEO's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

AVEO Stock Summary

  • With a year-over-year growth in debt of 162.28%, Aveo Pharmaceuticals Inc's debt growth rate surpasses 93.29% of about US stocks.
  • Revenue growth over the past 12 months for Aveo Pharmaceuticals Inc comes in at 602.69%, a number that bests 98.37% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AVEO comes in at -40.01% -- higher than that of only 10.68% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Aveo Pharmaceuticals Inc are MASS, DZSI, AVID, TACT, and AMSWA.
  • AVEO's SEC filings can be seen here. And to visit Aveo Pharmaceuticals Inc's official web site, go to www.aveooncology.com.

AVEO Valuation Summary

  • In comparison to the median Healthcare stock, AVEO's price/sales ratio is 315.79% higher, now standing at 15.8.
  • Over the past 140 months, AVEO's price/sales ratio has gone up 3.8.
  • Over the past 140 months, AVEO's EV/EBIT ratio has gone up 2.

Below are key valuation metrics over time for AVEO.

Stock Date P/S P/B P/E EV/EBIT
AVEO 2021-08-31 15.8 3.7 -4.0 -3.4
AVEO 2021-08-30 15.4 3.6 -3.9 -3.3
AVEO 2021-08-27 16.1 3.7 -4.0 -3.5
AVEO 2021-08-26 15.2 3.5 -3.8 -3.2
AVEO 2021-08-25 15.2 3.5 -3.8 -3.2
AVEO 2021-08-24 14.9 3.5 -3.8 -3.2

AVEO Growth Metrics

    Its 4 year price growth rate is now at -27.33%.
  • The 3 year price growth rate now stands at 0.04%.
  • Its 5 year net income to common stockholders growth rate is now at 103.82%.
AVEO's revenue has moved up $36,301,000 over the prior 34 months.

The table below shows AVEO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 42.295 -57.257 -53.342
2021-09-30 25.535 -57.953 -57.591
2021-06-30 13.962 -55.768 -55.616
2021-03-31 7.155 -44.63 -49.325
2020-12-31 6.019 -37.983 -35.584
2020-09-30 5.897 -32.474 -28.541

AVEO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AVEO has a Quality Grade of D, ranking ahead of 14.08% of graded US stocks.
  • AVEO's asset turnover comes in at 0.147 -- ranking 224th of 682 Pharmaceutical Products stocks.
  • LXRX, SEEL, and OTLK are the stocks whose asset turnover ratios are most correlated with AVEO.

The table below shows AVEO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.147 0.931 -1.982
2021-03-31 0.083 0.981 -2.596
2020-12-31 0.095 1.000 -2.215
2020-09-30 0.099 1.000 -1.463
2020-06-30 0.499 1.000 -0.212
2020-03-31 0.587 1.000 0.334

AVEO Price Target

For more insight on analysts targets of AVEO, see our AVEO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.00 Average Broker Recommendation 1.12 (Strong Buy)

AVEO Stock Price Chart Interactive Chart >

Price chart for AVEO

AVEO Price/Volume Stats

Current price $3.97 52-week high $7.59
Prev. close $4.00 52-week low $3.06
Day low $3.95 Volume 17,538
Day high $4.13 Avg. volume 307,712
50-day MA $5.07 Dividend yield N/A
200-day MA $5.32 Market Cap 136.88M

AVEO Pharmaceuticals, Inc. (AVEO) Company Bio

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

AVEO Latest News Stream

Event/Time News Detail
Loading, please wait...

AVEO Latest Social Stream

Loading social stream, please wait...

View Full AVEO Social Stream

Latest AVEO News From Around the Web

Below are the latest news stories about Aveo Pharmaceuticals Inc that investors may wish to consider to help them evaluate AVEO as an investment opportunity.

Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies and AVEO Oncology (NASDAQ: AVEO) ("AVEO"), a commercial stage, oncology-focused biopharmaceutical company, today announced that they have entered into a research collaboration to develop and study a first-in-class antibody radio-conjugate (ARC) targeting ErbB3, also known as HER3. Actinium will utilize its AWE technology platform and extensive radiotherapy kn

Yahoo | February 22, 2022

AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma

Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib) Long-term data from pivotal TIVO-3 study continue to demonstrate durable disease control and positive trend for overall survival for FOTIVDA® (tivozanib) Data Presented at the ASCO 2022 GU Cancers Symposium BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced

Yahoo | February 14, 2022

AVEO Oncology Announces Participation at the 11th Annual SVB Leerink Global Healthcare Conference

BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 9:20 a.m. eastern time. A live webcast of the fireside chat can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the

Yahoo | February 3, 2022

AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium

First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two trials in progress posters presentations for the DEDUCTIVE HCC study and the recently initiated Phase 1b/2 IMMCO-1 study of tivozanib and atezolizumab in multiple immunologically cold tumors BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that

Yahoo | January 20, 2022

Investors three-year losses grow to 78% as the stock sheds US$41m this past week

Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So take a moment to...

Yahoo | January 11, 2022

Read More 'AVEO' Stories Here

AVEO Price Returns

1-mo -22.61%
3-mo 15.41%
6-mo -38.92%
1-year -41.45%
3-year -43.29%
5-year -47.07%
YTD -15.35%
2021 -18.72%
2020 -7.58%
2019 -60.98%
2018 -42.65%
2017 416.67%

Continue Researching AVEO

Here are a few links from around the web to help you further your research on Aveo Pharmaceuticals Inc's stock as an investment opportunity:

Aveo Pharmaceuticals Inc (AVEO) Stock Price | Nasdaq
Aveo Pharmaceuticals Inc (AVEO) Stock Quote, History and News - Yahoo Finance
Aveo Pharmaceuticals Inc (AVEO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6446 seconds.